AU642048B2 - Novel muramyldipeptide derivatives and influenza vaccine comprising the derivatives - Google Patents

Novel muramyldipeptide derivatives and influenza vaccine comprising the derivatives Download PDF

Info

Publication number
AU642048B2
AU642048B2 AU86849/91A AU8684991A AU642048B2 AU 642048 B2 AU642048 B2 AU 642048B2 AU 86849/91 A AU86849/91 A AU 86849/91A AU 8684991 A AU8684991 A AU 8684991A AU 642048 B2 AU642048 B2 AU 642048B2
Authority
AU
Australia
Prior art keywords
group
carbon atoms
influenza vaccine
vaccine
influenza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU86849/91A
Other languages
English (en)
Other versions
AU8684991A (en
Inventor
Kunio Ohkuma
Tetuya Oka
Masaharu Oki
Hideya Tsuge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemo Sero Therapeutic Research Institute Kaketsuken
Daiichi Pharmaceutical Co Ltd
Original Assignee
Chemo Sero Therapeutic Research Institute Kaketsuken
Daiichi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Sero Therapeutic Research Institute Kaketsuken, Daiichi Pharmaceutical Co Ltd filed Critical Chemo Sero Therapeutic Research Institute Kaketsuken
Publication of AU8684991A publication Critical patent/AU8684991A/en
Application granted granted Critical
Publication of AU642048B2 publication Critical patent/AU642048B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • C07K9/005—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure containing within the molecule the substructure with m, n > 0 and m+n > 0, A, B, D, E being heteroatoms; X being a bond or a chain, e.g. muramylpeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/812—Liposome comprising an antibody, antibody fragment, antigen, or other specific or nonspecific immunoeffector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU86849/91A 1990-10-30 1991-10-29 Novel muramyldipeptide derivatives and influenza vaccine comprising the derivatives Ceased AU642048B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2-293336 1990-10-30
JP29333690 1990-10-30
JP29333590 1990-10-30
JP2-293335 1990-10-30

Publications (2)

Publication Number Publication Date
AU8684991A AU8684991A (en) 1992-05-07
AU642048B2 true AU642048B2 (en) 1993-10-07

Family

ID=26559366

Family Applications (1)

Application Number Title Priority Date Filing Date
AU86849/91A Ceased AU642048B2 (en) 1990-10-30 1991-10-29 Novel muramyldipeptide derivatives and influenza vaccine comprising the derivatives

Country Status (16)

Country Link
US (1) US5292506A (OSRAM)
EP (2) EP0680974A1 (OSRAM)
KR (1) KR920008064A (OSRAM)
CN (1) CN1062146A (OSRAM)
AU (1) AU642048B2 (OSRAM)
CA (1) CA2054228A1 (OSRAM)
FI (1) FI915089A7 (OSRAM)
HU (1) HUT62199A (OSRAM)
IE (1) IE913765A1 (OSRAM)
IL (1) IL99851A (OSRAM)
MX (1) MX9101820A (OSRAM)
NO (1) NO914233D0 (OSRAM)
NZ (1) NZ240369A (OSRAM)
PT (1) PT99389A (OSRAM)
RU (1) RU2074192C1 (OSRAM)
TW (1) TW207545B (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612037A (en) * 1994-07-26 1997-03-18 Connaught Laboratories, Inc. Influenza virus subunit conjugates
CA2451816A1 (en) * 2001-06-29 2003-01-09 Becton, Dickinson And Company Intradermal delivery of vaccines and gene therapeutic agents via microcannula
US20050169979A1 (en) * 2002-07-03 2005-08-04 Dov Michaeli Liposomal vaccine
JP2005535663A (ja) * 2002-07-03 2005-11-24 アフトン コーポレーション リポソームワクチン
US20040247661A1 (en) * 2002-07-03 2004-12-09 Dov Michaeli Liposomal vaccine
US20050123550A1 (en) * 2003-05-12 2005-06-09 Laurent Philippe E. Molecules enhancing dermal delivery of influenza vaccines
US7588774B2 (en) * 2003-05-12 2009-09-15 Becton, Dickinson And Company Molecules enhancing dermal delivery of influenza vaccines
AR056245A1 (es) 2003-06-19 2007-10-03 Bestewil Holding Bv Membranas virales reconstituidas funcionales que contienen un coadyuvante
EP1708742A4 (en) * 2003-12-05 2008-11-05 Becton Dickinson Co METHOD FOR IMPROVING THE IMMUNE RESPONSE IN THE INTRADERMAL COMPARTMENT AND USEFUL LINKS THEREFOR
EP2578229B1 (en) 2004-09-09 2013-07-10 Novartis Vaccines and Diagnostics GmbH Decreasing potential iatrogenic risks associated with vaccine antigens
EP1807116B1 (en) 2004-11-03 2015-05-06 Novartis Vaccines and Diagnostics, Inc. Influenza vaccination
US20060121055A1 (en) * 2004-12-06 2006-06-08 Becton, Dickinson And Company, Inc. Compositions with enhanced immunogenicity
CN101100483B (zh) * 2006-07-07 2011-12-07 中国医学科学院药物研究所 胞壁酰二肽的类似物
US8383110B2 (en) 2006-08-25 2013-02-26 Agency For Science, Technology And Research Modulators of Candida hyphal morphogenesis and uses thereof
US20090060889A1 (en) * 2007-03-12 2009-03-05 Von Hofe Eric Ii-RNAi involved Ii suppression in cancer immunotherapy
EP3012330A1 (en) 2010-09-07 2016-04-27 Novartis AG Generic assays for detection of mammalian reovirus
US9884084B2 (en) 2012-05-16 2018-02-06 Snu R&Db Foundation Bone loss preventing and bone regeneration or bone formation promoting pharmaceutical composition comprising muramyl dipeptide

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5787590A (en) * 1989-06-29 1991-01-03 Sandoz Ltd. Muramyl dipeptide derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6042398A (ja) * 1983-08-18 1985-03-06 Toshiyuki Hamaoka ムラミルジペプチド活性エステル誘導体
JPH0688911B2 (ja) * 1985-06-06 1994-11-09 国立予防衛生研究所長 インフルエンザワクチン及びその製造方法
US4895835A (en) * 1987-11-20 1990-01-23 Nisshin Oil Mills, Ltd. Muramyl peptide derivatives and use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5787590A (en) * 1989-06-29 1991-01-03 Sandoz Ltd. Muramyl dipeptide derivatives

Also Published As

Publication number Publication date
IE913765A1 (en) 1992-05-22
NO914233D0 (no) 1991-10-29
EP0487909A3 (en) 1992-08-12
US5292506A (en) 1994-03-08
HU913398D0 (en) 1992-01-28
IL99851A0 (en) 1992-08-18
FI915089L (fi) 1992-05-01
FI915089A7 (fi) 1992-05-01
MX9101820A (es) 1992-06-05
EP0487909A2 (en) 1992-06-03
IL99851A (en) 1996-06-18
EP0680974A1 (en) 1995-11-08
TW207545B (OSRAM) 1993-06-11
CA2054228A1 (en) 1992-05-01
FI915089A0 (fi) 1991-10-29
PT99389A (pt) 1992-09-30
KR920008064A (ko) 1992-05-27
RU2074192C1 (ru) 1997-02-27
AU8684991A (en) 1992-05-07
NZ240369A (en) 1993-09-27
HUT62199A (en) 1993-04-28
CN1062146A (zh) 1992-06-24

Similar Documents

Publication Publication Date Title
AU642048B2 (en) Novel muramyldipeptide derivatives and influenza vaccine comprising the derivatives
KR101202553B1 (ko) 신규 당지질 보조제 조성물
US4396607A (en) Muramyl peptide derivatives and pharmaceutical compositions
CN116134020A (zh) 包含至少一个式-nh-cx-a或-nh-cx-nh-a的末端基团的脂质化合物、含有它们的组合物及其用途
US8282938B2 (en) Immunogenic compositions comprising liposomes and an influenza PB2 CTL epitope obtained from the highly pathogenic H5N1 strain
EP0013651A1 (fr) Muramyl-peptides fixés sur polymères peptidiques et médicaments les contenant
CN101374551B (zh) 新的糖脂佐剂组合物
JP3697189B2 (ja) リン脂質の塩基交換方法
JPH05229960A (ja) 新規インフルエンザワクチン
US5152999A (en) Liposome preparation
JPS632922A (ja) ドラツグキヤリア
WO1979000802A1 (fr) Nouveaux composes esters de muramyl-peptide et leurs applications dans les compositions pharmaceutiques et reactifs de laboratoire
JP3539739B2 (ja) 新規ムラミルジペプチド誘導体
Pietrobon et al. Lipopeptides and Their Effects on the Immune System: Use as Vaccine Components
JPH07121871B2 (ja) インフルエンザワクチン凍結乾燥製剤
JP2665633B2 (ja) グリセロール誘導体
JPS6188886A (ja) 酵素法リン脂質長鎖アルコ−ル誘導体の製法
RU2133625C1 (ru) Способ получения живой коревой вакцины для перорального применения и способ иммунизации против кори
JP2777258B2 (ja) ムラミルジペプチド含有脂質膜構造体
JPH057765A (ja) リポソーム
RU2005102396A (ru) ВАКЦИННЫЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ЛИПОПОЛИСАХАРИДЫ ИММУНОТИПА L2 И/ИЛИ L3, ПРОИСХОДЯЩИЕ ИЗ ШТАММА NEISSERIA MENINGITIDIS IgtB-
HK1128078B (en) Novel glycolipid adjuvant compositions
JPH0420293A (ja) リン脂質誘導体の製造方法
JPH1171266A (ja) キサンチン誘導体のリポソーム製剤